Beam Therapeutics Inc. News
Cathie Wood Watch: Ark Buys Into Slumping Software Firm, Sells 3D Printing
Wood's flagship Ark Innovation ETF has sunk 54% so far this year, and is down 73% from its February 2021 peak.
Cathie Wood Watch: This Firm Programs Cells, Using DNA as Code
Wood's Ark Investment Management bought a series of biotech stocks, as it has done repeatedly in recent sessions.
Stock Market Today: Inflation Fears Pound Tech, Omicron Wave Tests Growth Bets; Bond Yields Hit 1.8%
Wall Street looks set to extend last week's declines, with tech stocks leading to the downside, ahead of a key reading of December inflation, Jerome Powell testimony and the start of the fourth quarter earnings season.
Beam Therapeutics Stock Active After $1.35 Billion Pfizer Drug Development Deal
Boston-based Beam Therapeutics has agreed to a potential $1.35 billion drug development deal with pharma giant Pfizer.
Intellia Therapeutics Leads Gene-Editing Stock Rally
Intellia Therapeutics rises and other gene-editing stocks follow suit.
Bourbon Whiskey -- A Brief History of This All-American Drink
Why not celebrate this Fourth of July by savoring some bourbon, a truly American spirit. Here's a brief history of our national whiskey.
President Biden To Sign Bill Preventing Rail Strike 'Catastrophe' Following Senate Approval
"Working together, we have spared this country a Christmas catastrophe in our grocery stores, in our workplaces, and in our communities," President Biden said
Marvell Stock Slumps On Q3 Earnings Miss, Soft Chip Sector Outlook
"Inventory reductions, in particular at our storage customers, are impacting our near-term results and guidance," said CEO Matt Murphy.
Elon Musk's Latest Twitter Move Looks Like an Act of Desperation
Twitter is desperate for revenue. It has a $13 billion debt burden, but hasn’t showed a profit for eight of the last 10 years.